Search

Your search keyword '"Rubino, Manila"' showing total 139 results
Start Over Author "Rubino, Manila"
139 results on '"Rubino, Manila"'

1. Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis

Author

Rubino, Manila, Di Stasio, Giuseppe Danilo, Bodei, Lisa, Papi, Stefano, Rocca, Paola Anna, Ferrari, Mahila Esmeralda, Fodor, Cristiana Iuliana, Bagnardi, Vincenzo, Frassoni, Samuele, Mei, Riccardo, Fazio, Nicola, Ceci, Francesco, and Grana, Chiara Maria

Published
2024
Full Text
View/download PDF

2. Central Neck Dissection in Papillary Thyroid Carcinoma: Benefits and Doubts in the Era of Thyroid Lobectomy.

Author

Zocchi, Jacopo, Giugliano, Gioacchino, Mossinelli, Chiara, Mariani, Cecilia, Pietrobon, Giacomo, Bandi, Francesco, Malpede, Stefano, Grosso, Enrica, Manzoni, Marco Federico, De Fiori, Elvio, Mauri, Giovanni, Rubino, Manila, Tagliabue, Marta, and Ansarin, Mohssen

Subjects
PATIENT selection, HEMITHYROIDECTOMY, PROPORTIONAL hazards models, CANCER relapse, VOCAL cords, NECK dissection
Abstract

Introduction: Surgery is still the main line of treatment for papillary thyroid cancer (PTC) with a current trend for de-intensified treatment based on an excellent prognosis. The role of a routine prophylactic central neck dissection (PCND) is still debated as its impact on oncologic outcomes has never been cleared by a randomized clinical trial. In this study, we aimed to report our long-standing experience in PCND and its potential contemporary role in the treatment of PTC. Methods: A retrospective institutional review was performed on all patients who underwent operation for PTC including PCND between 1998 and 2021. The primary outcomes were the rate of central lymph node metastases (CLNMs), cancer recurrence and incidence of complications. Survivals were analyzed using the Kaplan–Meier estimator and Cox proportional hazard models. Results: A total of 657 patients were included in this study with a median follow-up of 78 months (48–114 months). Two hundred and one patients presented occult CLNMs (30.6%). The presence of a pathological node represented the unique reason for a completion thyroidectomy and I131 therapy in 12.5% of the population. Age lower than 55 years, microscopic or macroscopic extra-thyroid extension (ETE) and multifocality were independent factors predicting CLNMs. The rate of recurrence in the whole population was 2.7% (18 patients). Five-year and ten-year disease-free survival (DFS) was 96.5% (94.7–97.7) and 93.3% (90.3–95.5), respectively. Two patients relapsed in the central neck compartment (0.3%). Age (>55 years), pathological staging (pT) and extranodal extension (ENE) were independent factors associated with a worse DFS. The rate of temporary and permanent vocal fold palsy was 12.8% and 1.8%, respectively, and did not depend on the type of surgical procedure performed. Hypoparathyroidism was temporary in 42.2% and permanent in 11.9% of the patients. A sub-analysis upon cT1b-T2 patients treated primarily with thyroid lobectomy and ipsilateral PCND demonstrated a 2.6% rate of permanent hypoparathyroidism. Conclusions: PCND allows for a high disease-free survival and a proper selection of patients needing adjuvant treatment, in particular, those treated with a unilateral procedure. On the other hand, bilateral approach is burdened by a not-neglectable rate of permanent hypoparathyroidism. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. New Approaches in Medical Therapies

Author

Rubino, Manila, Spada, Francesca, Laffi, Alice, Fazio, Nicola, Beretta, Giordano, editor, Berruti, Alfredo, editor, Bombardieri, Emilio, editor, Fazio, Nicola, editor, and Goletti, Orlando, editor

Published
2021
Full Text
View/download PDF

5. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Author

Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R., La Salvia, Anna, Hofland, Johannes, Hernando, Jorge, Sonbol, Mohamad B., Garcia-Carbonero, Rocio, Capdevila, Jaume, de Herder, Wouter W., Koumarianou, Anna, Kaltsas, Gregory, Rossi, Maura, Grozinsky-Glasberg, Simona, Oleinikov, Kira, Boselli, Sabrina, Tamayo, Darina, Bagnardi, Vincenzo, Laffi, Alice, Rubino, Manila, and Spada, Francesca

Published
2021
Full Text
View/download PDF

6. Venous thromboembolism in pancreatic neuroendocrine neoplasm: a cohort study

Author

Gervaso, Lorenzo, primary, Laffi, Alice, additional, Gaeta, Aurora, additional, Gandini, Sara, additional, Boldrini, Laura, additional, Meneses-Medina, Monica Isabel, additional, Rubino, Manila, additional, Benini, Lavinia, additional, Borghesani, Michele, additional, Algeri, Laura, additional, Curigliano, Giuseppe, additional, Spada, Francesca, additional, Cella, Chiara Alessandra, additional, and Fazio, Nicola, additional

Published
2024
Full Text
View/download PDF

10. Multimodal treatment for resectable neuroendocrine carcinoma of the cervix

Author

Valenza, Carmine, primary, Spada, Francesca, additional, Multinu, Francesco, additional, Benini, Lavinia, additional, Borghesani, Michele, additional, Algeri, Laura, additional, Rubino, Manila, additional, Pisa, Eleonora, additional, Gervaso, Lorenzo, additional, Cella, Chiara Alessandra, additional, Carinelli, Silvestro, additional, Bruni, Simone, additional, Schivardi, Gabriella, additional, Curigliano, Giuseppe, additional, Zanagnolo, Vanna, additional, Aletti, Giovanni, additional, Colombo, Nicoletta, additional, and Fazio, Nicola, additional

Published
2023
Full Text
View/download PDF

11. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, Spada, F, Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, and Spada, Francesca

Abstract

We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. Here, we are reporting data from consecutive patients enrolled between 1 June 2020, and 31 May 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021, and 17.4% in 2022. The median age for COVID-19 diagnosis was 60 years. Well-differentiated tumors, non-functioning, metastatic stage, and gastroenteropancreatic (GEP) primary sites represented most of the NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Diabetes mellitus and age at COVID-19 diagnosis > 70 years were significantly associated with COVID-19 mortality, whereas thoracic primary site with COVID-19 morbidity. A significant decrease in both hospitalization and pneumonia occurred in 2022 vs 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population of patients with NEN regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients with COVID-19 registries.

Published
2023

12. Multimodal treatment for resectable neuroendocrine carcinoma of the cervix

Author

Valenza, C, Spada, F, Multinu, F, Benini, L, Borghesani, M, Algeri, L, Rubino, M, Pisa, E, Gervaso, L, Cella, C, Carinelli, S, Bruni, S, Schivardi, G, Curigliano, G, Zanagnolo, V, Aletti, G, Colombo, N, Fazio, N, Valenza, Carmine, Spada, Francesca, Multinu, Francesco, Benini, Lavinia, Borghesani, Michele, Algeri, Laura, Rubino, Manila, Pisa, Eleonora, Gervaso, Lorenzo, Cella, Chiara Alessandra, Carinelli, Silvestro, Bruni, Simone, Schivardi, Gabriella, Curigliano, Giuseppe, Zanagnolo, Vanna, Aletti, Giovanni, Colombo, Nicoletta, Fazio, Nicola, Valenza, C, Spada, F, Multinu, F, Benini, L, Borghesani, M, Algeri, L, Rubino, M, Pisa, E, Gervaso, L, Cella, C, Carinelli, S, Bruni, S, Schivardi, G, Curigliano, G, Zanagnolo, V, Aletti, G, Colombo, N, Fazio, N, Valenza, Carmine, Spada, Francesca, Multinu, Francesco, Benini, Lavinia, Borghesani, Michele, Algeri, Laura, Rubino, Manila, Pisa, Eleonora, Gervaso, Lorenzo, Cella, Chiara Alessandra, Carinelli, Silvestro, Bruni, Simone, Schivardi, Gabriella, Curigliano, Giuseppe, Zanagnolo, Vanna, Aletti, Giovanni, Colombo, Nicoletta, and Fazio, Nicola

Abstract

Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy, and discussed at the European Institute of Oncology's Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient preferences.

Published
2023

13. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, Nicola, primary, Gervaso, Lorenzo, additional, Halfdanarson, Thorvardur R, additional, Sonbol, Mohamad, additional, Eiring, Rachel A, additional, Pusceddu, Sara, additional, Prinzi, Natalie, additional, Lombardi Stocchetti, Benedetta, additional, Grozinsky-Glasberg, Simona, additional, Gross, David J., additional, Walter, Thomas, additional, Robelin, Patrick, additional, Lombard-Bohas, Catherine, additional, Frassoni, Samuele, additional, Bagnardi, Vincenzo, additional, Antonuzzo, Lorenzo, additional, Sparano, Clotilde, additional, Massironi, Sara, additional, Gelsomino, Fabio, additional, Bongiovanni, Alberto, additional, Ranallo, Nicoletta, additional, Tafuto, Salvatore, additional, Rossi, Maura, additional, Cives, Mauro, additional, Rasul, Kakil Ibrahim, additional, Hamid, Hytham, additional, Chirco, Alessandra, additional, Squadroni, Michela, additional, La Salvia, Anna, additional, Hernando, Jorge, additional, Hofland, Johannes, additional, Koumarianou, Anna, additional, Boselli, Sabrina, additional, Tamayo, Darina, additional, Mazzon, Cristina, additional, Rubino, Manila, additional, and Spada, Francesca, additional

Published
2023
Full Text
View/download PDF

14. Observational Study on Antibody Response to COVID-19 Vaccines in PAtients with Gastro-Entero-PanCreatic Cancers and NeuroendocrIne NeoplAsms on Systemic TreatmEnts (VACCINATE)

Author

Laffi, Alice, primary, Gervaso, Lorenzo, additional, D’Ecclesiis, Oriana, additional, Gandini, Sara, additional, Riva, Agostino, additional, Passerini, Rita, additional, Spada, Francesca, additional, Pellicori, Stefania, additional, Rubino, Manila, additional, Cella, Chiara Alessandra, additional, Ravenda, Paola Simona, additional, Zampino, Maria Giulia, additional, and Fazio, Nicola, additional

Published
2023
Full Text
View/download PDF

15. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study

Author

Fazio, Nicola, Gervaso, Lorenzo, Halfdanarson, Thorvardur R, Sonbol, Mohamad, Eiring, Rachel A, Pusceddu, Sara, Prinzi, Natalie, Lombardi Stocchetti, Benedetta, Grozinsky-Glasberg, Simona, Gross, David J, Walter, Thomas, Robelin, Patrick, Lombard-Bohas, Catherine, Frassoni, Samuele, Bagnardi, Vincenzo, Antonuzzo, Lorenzo, Sparano, Clotilde, Massironi, Sara, Gelsomino, Fabio, Bongiovanni, Alberto, Ranallo, Nicoletta, Tafuto, Salvatore, Rossi, Maura, Cives, Mauro, Rasul, Kakil Ibrahim, Hamid, Hytham, Chirco, Alessandra, Squadroni, Michela, La Salvia, Anna, Hernando, Jorge, Hofland, Johannes, Koumarianou, Anna, Boselli, Sabrina, Tamayo, Darina, Mazzon, Cristina, Rubino, Manila, Spada, Francesca, Fazio, N, Gervaso, L, Halfdanarson, T, Sonbol, M, Eiring, R, Pusceddu, S, Prinzi, N, Lombardi Stocchetti, B, Grozinsky-Glasberg, S, Gross, D, Walter, T, Robelin, P, Lombard-Bohas, C, Frassoni, S, Bagnardi, V, Antonuzzo, L, Sparano, C, Massironi, S, Gelsomino, F, Bongiovanni, A, Ranallo, N, Tafuto, S, Rossi, M, Cives, M, Rasul, K, Hamid, H, Chirco, A, Squadroni, M, La Salvia, A, Hernando, J, Hofland, J, Koumarianou, A, Boselli, S, Tamayo, D, Mazzon, C, Rubino, M, and Spada, F

Subjects
COVID 19, neuroendocrine neoplasms
Abstract

Preliminary results regarding 85 patients of the INTENSIVE study have been published in 2021. Now we are reporting the 2-year analysis. We conducted a retrospective/prospective worldwide study on patients with neuroendocrine neoplasms (NENs) and a molecularly proven SARS-CoV-2 positivity. Here we are reporting data from consecutive patients enrolled between June 01, 2020, and May 31, 2022. Among the 118 contacted centers, 25 were active to enroll and 19 actively recruiting at the time of data cut-off for a total of 280 patients enrolled. SARS-CoV-2 positivity occurred in 47.5% of patients in 2020, 35.1% in 2021 and 17.4% in 2022. Median age at COVID-19 diagnosis was 60 years. Well differentiated tumors, non-functioning, metastatic stage and gastroenteropancreatic (GEP) primary site represented most of NENs. COVID-19-related pneumonia occurred in 22.8% of the total, with 61.3% of them requiring hospitalization; 11 patients (3.9%) needed sub-intensive or intensive care unit therapies and 14 patients died (5%), in 11 cases (3.9%) directly related to COVID-19. Thoracic and other NEN primary site were associated with hospitalization for COVID-19 and with sub-intensive or intensive care. A significant decrease in both hospitalization and pneumonia occurred in 2022 versus 2020. In our largest series of NEN patients with COVID-19, the NEN population is similar to the general population regardless of COVID-19. However, older age, non-GEP primary sites and diabetes mellitus should be carefully considered for increased COVID-19 morbidity and mortality. Relevant information could be derived by integrating our results with NENs patients included in other cancer patients and COVID-19 registries.

Published
2023

16. Multimodal treatment for resectable neuroendocrine carcinoma of the cervix

Author

Valenza, Carmine, Spada, Francesca, Multinu, Francesco, Benini, Lavinia, Borghesani, Michele, Algeri, Laura, Rubino, Manila, Pisa, Eleonora, Gervaso, Lorenzo, Cella, Chiara Alessandra, Carinelli, Silvestro, Bruni, Simone, Schivardi, Gabriella, Curigliano, Giuseppe, Zanagnolo, Vanna, Aletti, Giovanni, Colombo, Nicoletta, Fazio, Nicola, Valenza, C, Spada, F, Multinu, F, Benini, L, Borghesani, M, Algeri, L, Rubino, M, Pisa, E, Gervaso, L, Cella, C, Carinelli, S, Bruni, S, Schivardi, G, Curigliano, G, Zanagnolo, V, Aletti, G, Colombo, N, and Fazio, N

Subjects
NECC
Abstract

Non-metastatic neuroendocrine carcinoma of the cervix (NECC) is a rare and aggressive disease. Lacking prospective studies, the optimal multimodal treatment approach has not yet been clearly defined. This study aims to assess the clinical outcomes of patients with non-metastatic NECC treated with surgery and (neo)adjuvant chemotherapy, according to pathologic prognostic factors and multimodal treatments received. We retrospectively examined data from patients with non-metastatic NECC candidate to receive surgery and (neo)adjuvant chemotherapy, and discussed at the European Institute of Oncology's Multidisciplinary Neuroendocrine Tumor Board, between January 2003 and December 2021. Primary endpoints were event-free survival and overall survival. A total of 27 consecutive patients were evaluated, 15 with early stage NECC and 12 with a locally advanced NECC. Eight patients received neoadjuvant and 19 adjuvant platinum-based chemotherapy; 14 received adjuvant pelvic radiotherapy, half with external-beam radiation therapy alone, and half combined with brachytherapy. No patients progressed or relapsed during (neo)adjuvant chemotherapy. The median event-free survival was 21.1 months and the median overall survival was 33.0 months. Pathological FIGO stage ≥ IIB, adjuvant external-beam radiation therapy with or without brachytherapy emerged as significant and independent prognostic factors for event-free survival. Brachytherapy was also prognostic for overall survival. Non-metastatic NECC requires a multimodal approach, mainly weighted on the FIGO stage. The addition of brachytherapy should be considered, especially in patients with locally advanced disease. Because of the scarcity of robust clinical data, treatment strategy should be discussed in multidisciplinary board, taking into account patient preferences.

Published
2023

21. Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series

Author

Fazio, Nicola, primary, Maisonneuve, Patrick, additional, Spada, Francesca, additional, Gervaso, Lorenzo, additional, Cella, Chiara Alessandra, additional, Pozzari, Marta, additional, Zerini, Dario, additional, Pisa, Eleonora, additional, Fumagalli, Caterina, additional, Barberis, Massimo, additional, Laffi, Alice, additional, Grana C., Chiara Maria, additional, Orsolini, Gianmarco, additional, Prestianni, Pierpaolo, additional, Bonomo, Guido, additional, Funicelli, Luigi, additional, Bertani, Emilio, additional, Queirolo, Paola, additional, Ravizza, Davide, additional, Rubino, Manila, additional, Tosti, Giulio, additional, and Pennacchioli, Elisabetta, additional

Published
2022
Full Text
View/download PDF

22. Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes

Author

Cella, Chiara Alessandra, primary, Spada, Francesca, additional, Berruti, Alfredo, additional, Bertolini, Francesco, additional, Mancuso, Patrizia, additional, Barberis, Massimo, additional, Pisa, Eleonora, additional, Rubino, Manila, additional, Gervaso, Lorenzo, additional, Laffi, Alice, additional, Pellicori, Stefania, additional, Radice, Davide, additional, Zorzino, Laura, additional, Calleri, Angelica, additional, Funicelli, Luigi, additional, Petralia, Giuseppe, additional, and Fazio, Nicola, additional

Published
2022
Full Text
View/download PDF

24. Vitamin D levels and chronic hepatitis C

Author

Morisco, Filomena, Colao, Annamaria, Guarino, Maria, Lembo, Vincenzo, Granata, Rocco, Donnarumma, Laura, Auriemma, Francesco, Mariniello, Anna, Mazzone, Giovanna, Di Somma, Carolina, Rubino, Manila, Cariati, Federica, Pivonello, Claudia, Loperto, Ilaria, and Caporaso, Nicola

Published
2013
Full Text
View/download PDF

25. Gastric Neuroendocrine Tumors (g-NETs): A Systematic Review of the Management and Outcomes of Type 3 g-NETs.

Author

Laffi, Alice, Lania, Andrea Gerardo Antonio, Ragni, Alberto, Di Vito, Valentina, Liccardi, Alessia, Rubino, Manila, Sesti, Franz, Colao, Annamaria, and Faggiano, Antongiulio

Subjects
STOMACH tumors, ONLINE information services, MEDICAL information storage & retrieval systems, LYMPHADENECTOMY, CANCER chemotherapy, SYSTEMATIC reviews, DISEASE incidence, TREATMENT effectiveness, CANCER patients, GASTRECTOMY, NEUROENDOCRINE tumors, DECISION making, MEDLINE, RARE diseases, TUMOR grading
Abstract

Simple Summary: Gastric well-differentiated neuroendocrine tumors (g-NETs) occur in 5–15% of cases of neuroendocrine neoplasms in the gastrointestinal tract, and they mostly present quite indolent biological behavior. Furthermore, among the g-NETs, the type 3 versions represent the most aggressive subcategory, with the highest incidence of lymph-vascular infiltration and metastases at diagnosis. For these reasons, a more interventional approach to the management of type 3 g-NETs has been generally shared by the scientific community. However, a case-by-case discussion amongst a multidisciplinary NET-dedicated team revealed that partial or complete gastrectomy with lymphadenectomy had become an out-of-proportion indication within such cases regarding small and/or low-grade lesions. The aim of this systematic review was to assess the real-life approaches to type 3 g-NETs and identify some of the prognostic factors that might impact management choices. We found that size and gastric wall infiltration and grading may represent three factors that should be taken into account to better manage type 3 g-NETs. Purpose: to collect data from real-life experiences of the management of type 3 g-NETs and identify possible prognostic factors that may impact the decision-making process. Methods: We performed a systematic review of the literature on type 3 g-NET management using the PubMed, MEDLINE, and Embase databases. We included cohort studies, case series, and case reports written in the English language. Results: We selected 31 out of 556 articles from between 2001 and 2022. In 2 out of the 31 studies, a 10 mm and 20 mm cut-off size were respectively associated with a higher risk of gastric wall infiltration and/or lymph node and distant metastasis at diagnosis. The selected studies reported a higher risk of lymph node or distant metastasis at diagnosis in the case of muscularis propria infiltration or beyond, irrespective of the dimensions or grading. From these findings, size, grading, and gastric wall infiltration seem to be the most relevant factors in management staff making choices and prognoses of type 3 g-NET patients. We produced a hypothetical flowchart for a standardized approach to these rare diseases. Conclusion: Further prospective analyses are needed to validate the prognostic impact of the use of size, grading, and gastric wall infiltration as prognostic factors in the management of type 3 g-NETs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. A Retrospective Analysis of the Correlation between Functional Imaging and Clinical Outcomes in Grade 3 Neuroendocrine Tumors (NETs G3)

Author

Laffi, Alice, primary, Colandrea, Marzia, additional, Buonsanti, Giuseppe, additional, Frassoni, Samuele, additional, Bagnardi, Vincenzo, additional, Spada, Francesca, additional, Pisa, Eleonora, additional, Barberis, Massimo, additional, Rubino, Manila, additional, Grana, Chiara Maria, additional, Ceci, Francesco, additional, and Fazio, Nicola, additional

Published
2021
Full Text
View/download PDF

30. Prevalence of Central Compartment Lymph Node Metastases in Papillary Thyroid Micro-Carcinoma: A Retrospective Evaluation of Predictive Preoperative Features

Author

Tagliabue, Marta, primary, Giugliano, Gioacchino, additional, Mariani, Maria Cecilia, additional, Rubino, Manila, additional, Grosso, Enrica, additional, Chu, Francesco, additional, Calastri, Anna, additional, Maffini, Fausto Antonio, additional, Mauri, Giovanni, additional, De Fiori, Elvio, additional, Manzoni, Marco Federico, additional, and Ansarin, Mohssen, additional

Published
2021
Full Text
View/download PDF

31. Corrigendum to ‘Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study’ [European Journal of Cancer 154 (2021) 246-252]

Author

Fazio, Nicola, primary, Gervaso, Lorenzo, additional, Halfdanarson, Thorvardur R., additional, La Salvia, Anna, additional, Hofland, Johannes, additional, Hernando, Jorge, additional, Sonbol, Mohamad B., additional, Garcia-Carbonero, Rocio, additional, Capdevila, Jaume, additional, de Herder, Wouter W., additional, Koumarianou, Anna, additional, Kaltsas, Gregory, additional, Rossi, Maura, additional, Grozinsky-Glasberg, Simona, additional, Oleinikov, Kira, additional, Boselli, Sabrina, additional, Tamayo, Darina, additional, Bagnardi, Vincenzo, additional, Laffi, Alice, additional, Rubino, Manila, additional, and Spada, Francesca, additional

Published
2021
Full Text
View/download PDF

33. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study

Author

Fazio, Nicola Gervaso, Lorenzo Halfdanarson, Thorvardur R. and La Salvia, Anna Hofland, Johannes Hernando, Jorge Sonbol, Mohamad B. Garcia-Carbonero, Rocio Capdevila, Jaume de Herder, Wouter W. Koumarianou, Anna Kaltsas, Gregory Rossi, Maura Grozinsky-Glasberg, Simona Oleinikov, Kira Boselli, Sabrina Tamayo, Darina Bagnardi, Vincenzo Laffi, Alice and Rubino, Manila Spada, Francesca

Abstract

Background: Specific data regarding coronavirus disease 2019 (COVID-19) in pa-tients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome cor-onavirus 2 (SARS-CoV-2) positive. Material and methods: This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating pa-tients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. Results: Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31st, 2021, eight recruiting centres enrolled 89 pa-tients. The median age was 64 years at the time of COVID-19 diagnosis. Most patients had metastatic, non-functioning, low-/intermediate-grade gastroenteropancreatic NENs on treat-ment with somatostatin analogues and radioligand therapy. Most of them had comorbidities. Only 8% of patients had high-grade NENs and 12% were receiving chemotherapy. Most pa-tients had symptoms or signs of COVID-19, mainly fever and cough. Only 3 patients under-went sub-intensive treatment, whereas most of them received medical therapies, mostly antibiotics. In two third of cases, no changes occurred for the anti-NEN therapy. More than 80% of patients completely recovered without sequelae, whereas 7.8% patients died due to COVID-19. Conclusions: Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy. (C) 2021 Elsevier Ltd. All rights reserved.

Published
2021

35. INTENSIVE: InterNaTional rEgistry oN Sars-cov-2 posItiVe nEuroendocrine neoplasm patients.

Author

Spada, Francesca, primary, Gervaso, Lorenzo, additional, La Salvia, Anna, additional, Garcia-Carbonero, Rocio, additional, Hernando, Jorge, additional, Capdevila, Jaume, additional, Hofland, Johannes, additional, de Herder, Wouter, additional, Koumarianou, Anna, additional, Rossi, Maura, additional, Boselli, Sabrina, additional, Tamayo, Darina, additional, Bagnardi, Vincenzo, additional, Laffi, Alice, additional, Rubino, Manila, additional, Sonbol, Mohamad Bassam, additional, Fazio, Nicola, additional, and Halfdanarson, Thorvardur Ragnar, additional

Published
2021
Full Text
View/download PDF

36. Brain Cystic Metastases in a Patient with Advanced Atypical Lung Carcinoid

Author

Fazio, Nicola, primary, Laffi, Alice, additional, Spada, Francesca, additional, Rubino, Manila, additional, Zerini, Dario, additional, Di Meco, Francesco, additional, Casali, Cecilia, additional, Bonomo, Guido, additional, Maria Grana, Chiara, additional, Funicelli, Luigi, additional, Pisa, Eleonora, additional, Bertani, Emilio, additional, Ravizza, Davide, additional, and Fazio, Nicola, additional

Published
2020
Full Text
View/download PDF

39. Metronomic and metronomic-like therapies in neuroendocrine tumors – Rationale and clinical perspectives

Author

Lambrescu, Ioana, primary, Fica, Simona, additional, Martins, Diana, additional, Spada, Francesca, additional, Cella, Chiara, additional, Bertani, Emilio, additional, Rubino, Manila, additional, Gibelli, Bianca, additional, Grana, Chiara, additional, Bonomo, Guido, additional, Funicelli, Luigi, additional, Ravizza, Davide, additional, Pisa, Eleonora, additional, Zerini, Dario, additional, Ungaro, Antonio, additional, and Fazio, Nicola, additional

Published
2017
Full Text
View/download PDF

40. Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors

Author

Milione, Massimo, primary, Maisonneuve, Patrick, additional, Pellegrinelli, Alessio, additional, Pusceddu, Sara, additional, Centonze, Giovanni, additional, Dominoni, Francesca, additional, Brambilla, Cecilia, additional, Rubino, Manila, additional, Faggiano, Antongiulio, additional, Buzzoni, Roberto, additional, Concas, Laura, additional, Giacomelli, Luca, additional, Coppa, Jorgelina, additional, Mazzaferro, Vincenzo, additional, and de Braud, Filippo, additional

Published
2016
Full Text
View/download PDF

41. Analysis of germline VEGF-A SNPs allows the identification of a subgroup of ATA low-intermediate risk DTC (differentiated thyroid cancer) patients with poor probability to develop recurrences

Author

Marotta, Vincenzo, primary, Sciammarella, Concetta, additional, Capasso, Mario, additional, Testori, Alessandro, additional, Gambardella, Claudio, additional, Grasso, Marica, additional, Rubino, Manila, additional, De, Palma Maurizio, additional, Grazia, Chiofalo Maria, additional, Pivonello, Claudia, additional, Pivonello, Rosario, additional, Santini, Luigi, additional, Pezzullo, Luciano, additional, Colao, Annamaria, additional, and Faggiano, Antongiulio, additional

Published
2016
Full Text
View/download PDF

43. Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.

Author

Milione, Massimo, Maisonneuve, Patrick, Pellegrinelli, Alessio, Pusceddu, Sara, Centonze, Giovanni, Dominoni, Francesca, Brambilla, Cecilia, Rubino, Manila, Faggiano, Antongiulio, Buzzoni, Roberto, Concas, Laura, Giacomelli, Luca, Coppa, Jorgelina, Mazzaferro, Vincenzo, and de Braud, Filippo

Abstract

Purpose: Abnormal expression of succinate dehydrogenase, (SDH), in particular of the B subunit (SDHB), is implicated in the pathogenesis of neuroendocrine tumors. This study evaluates the distribution of SDHB in WHO grading G1 and G2 intestinal, well-differentiated neuroendocrine tumors and corresponding lymph node or liver metastases. Methods: We collected ileal well-differentiated neuroendocrine tumors specimens from consecutive patients with prior primary resection and distant synchronous or metachronous liver metastases. We obtained 195 specimens from primary tumors ( n = 106) and metastases ( n = 89). The expression (E) of SDHB and the immunostaining intensity (I) were evaluated semiquantitatively and combined into a single score. SDHB score was evaluated in primitive tumor and metastatic specimens. Results: SDHB was found in all tumor cells. Mean SDHB expression was 72.7 % ± 17.1 % in primitive specimens and 27.9 % ± 24.6 % in metastatic specimens ( p < 0.0001). SDH intensity was higher in primitive specimens ( p < 0.0001). SDHB score was 9-12 in 96 specimens of the primitive group and 2 metastatic specimens ( p < 0.0001). None of the analyzed parameters was predictive of overall survival in the primitive subset. In the metastatic subset, loss of SDHB expression, intensity, and score were prognostic factors for survival. Lower expression and intensity of SDHB in metastatic lesions were associated with longer overall survival. When combining SDHB score and Ki-67 % in the metastatic subset, a lower SDHB score was associated with prolonged overall survival, independently from Ki-67 %. Conclusions: SDHB score was different in primitive and metastatic specimens. The combination of SDHB score and Ki-67 % was a stronger predictor of overall survival than Ki-67 % alone. This stratification might help predict survival. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

44. Hypovitaminosis D in adolescents living in the land of sun is correlated with incorrect life style: a survey study in Campania region

Author

Colao, Annamaria, primary, Muscogiuri, Giovanna, additional, Rubino, Manila, additional, Vuolo, Laura, additional, Pivonello, Claudia, additional, Sabatino, Pasquale, additional, Pizzo, Mara, additional, Campanile, Gelsomina, additional, Fittipaldi, Rosa, additional, Lombardi, Gaetano, additional, and Di Somma, Carolina, additional

Published
2014
Full Text
View/download PDF

45. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib

Author

Marotta, Vincenzo, primary, Di Somma, Carolina, additional, Rubino, Manila, additional, Sciammarella, Concetta, additional, Modica, Roberta, additional, Camera, Luigi, additional, Del Prete, Michela, additional, Marciello, Francesca, additional, Ramundo, Valeria, additional, Circelli, Luisa, additional, Buonomano, Pasqualina, additional, Colao, Annamaria, additional, and Faggiano, Antongiulio, additional

Published
2014
Full Text
View/download PDF

46. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication

Author

Marotta, Vincenzo, primary, Di Somma, Carolina, additional, Rubino, Manila, additional, Sciammarella, Concetta, additional, Del Prete, Michela, additional, Marciello, Francesca, additional, Ramundo, Valeria, additional, Circelli, Luisa, additional, Buonomano, Pasqualina, additional, Modica, Roberta, additional, Vitale, Mario, additional, Colao, Annamaria, additional, and Faggiano, Antongiulio, additional

Published
2014
Full Text
View/download PDF

47. Cinacalcet hydrochloride more efficiently controls serum calcium levels in mild-asymptomatic primary hyperparathyroidism without surgery criteria, as compared with surgical cases

Author

Marotta, Vincenzo, primary, di, Somma Carolina, additional, Rubino, Manila, additional, del, Prete Michela, additional, Marciello, Francesca, additional, Ramundo, Valeria, additional, Sciammarella, Concetta, additional, Buonomano, Pasqualina, additional, Carratu, Annachiara, additional, de, Luca di Roseto Chiara, additional, Colao, Annamaria, additional, and Faggiano, Antongiulio, additional

Published
2014
Full Text
View/download PDF

50. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks.

Author

Fanciulli, Giuseppe, Di Molfetta, Sergio, Dotto, Andrea, Florio, Tullio, Feola, Tiziana, Rubino, Manila, de Cicco, Federica, Colao, Annamaria, and Faggiano, Antongiulio

Subjects
IMMUNE checkpoint inhibitors, PARAGANGLIOMA, PHEOCHROMOCYTOMA, SYMPATHETIC nervous system, AUTONOMIC nervous system
Abstract

Pheochromocytoma and paraganglioma are neuroendocrine neoplasms, originating in the adrenal medulla and in parasympathetic and sympathetic autonomic nervous system ganglia, respectively. They usually present as localized tumours curable with surgery. However, these tumours may exhibit heterogeneous clinical course, ranging from no/minimal progression to aggressive (progressive/metastatic) behavior. For this setting of patients, current therapies are unsatisfactory. Immune checkpoint inhibitors have shown outstanding results for several types of solid cancers. We therefore aimed to summarize and discuss available data on efficacy and safety of current FDA-approved immune checkpoint inhibitors in patients with pheochromocytoma and paraganglioma. After an extensive search, we found 15 useful data sources (four full-published articles, four supplements of scientific journals, seven ongoing registered clinical trials). The data we detected, even with the limit of the small number of patients treated, make a great expectation on the therapeutic use of immune checkpoint inhibitors. Besides, the newly detected predictors of response will (hopefully) be of great helps in selecting the subset of patients that might benefit the most from this class of drugs. Finally, new trials are in the starting blocks, and they are expected to shed in the next future new light on a therapy, which is considered a milestone in oncology. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results